Work | Tumor Initiating Cells
Natural Killer Cell Transplant Pilot Study
This study will assess the feasibility of utilizing a reduced intensity conditioning regimen, in the setting of haploidentical transplantation, for patients with recurrent acute lymphoblastic leukemia (ALL), AML and high risk or refractory solid tumors.
In addition, the feasibility and safety of administering post-transplant NK cell infusions will be evaluated. Data obtained from this study will help determine the efficacy of allogeneic HSCT in the treatment of pediatric sarcomas and add to the small body of literature utilizing haploidentical HSCT to treat acute leukemia in pediatric patients. This study will also further elucidate the role of NK cells in mediating a graft versus tumor effect in allogeneic HSCT. The main benefit to society is that this study will explore a novel therapy for children with highly refractory cancer who are felt to be incurable with conventional approaches. If feasibility is demonstrated, and there is evidence of anti-tumor activity, then this will open up a new area of clinical research to better define the efficacy of this approach for specific childhood malignancies.
Relevant Articles and Links
- Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors (Blood)
- Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia (ASCO)
- Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors (ClinicalTrials.gov)
Therapeutic Development Project Links
- Nifurtimox Phase I Clinical Trial
- Nifurtimox Phase II Clinical Trial
- Neuroblastoma Drug Discovery Program
- Rapamycin + Vinblastine Phase I Study
- Patient-specific Therapeutic Development for Neuroblastoma
- Oncolytic Virus Program
- Development Program for Neuroblastoma-specific Oncolytic Virus
- Natural Killer Cell Transplant Pilot Study
- Phase I Clinical Trial of HSV Oncolytic Virus